Search results for: Health Policy and Regulation
Filter search results
New OHE Seminar Briefing: Interventions that Encourage High-value Nursing Home Care: Lessons for the UK
11 August 2017
…Grabowski from Harvard University. In this briefing Professor Grabowski explains that both the US and UK devote significant financial resources to nursing home care, and both have relied on regulation…
Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS
29 August 2018
…for the English National Health Service (NHS) for the same period at 8.0%. However, NHS Digital reported much-reduced medicines expenditure growth for England of 3.5% for 2016/17, suggesting a complex…
OHE Lunchtime Seminar: Incentives for R&D, Competition and Intertemporal Effects of Payment Rules for Cures
13 May 2019
…regulation and competition policy and has appeared in many academic journals. Pedro Pita Barros has also contributed to several books and has published several books on health economics. He also…
OHE has an Opening for an Industrial Economist
20 November 2019
The Office of Health Economics wishes to recruit a well-qualified, highly motivated and energetic economist with an industrial organisation background applied to the health care sector, health care systems and/or…
OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?
16 January 2020
…number of international bodies (including the World Bank, the WHO and the IMF) and pharmaceutical companies and health care insurance companies (including BUPA in a Monopolies and Mergers Commission hearing)….
Sources of Information for Prescribing Doctors in Britain
9 January 1977
…voluntary and statutory controls on their sales promotion. Both the industry’s Code of Practice and the Government’s regulations under the 1968 Medicines Act are being considerably tightened in order to…
To Publish or Not: Experience and Evidence About Publishing Hospital Outcomes Data
1 February 2004
…and the Netherlands (Marshall and Brook, 2002). Whilst political and regulatory attitudes differ across countries, the economic motivations are often similar. Concern with escalating health care costs and regional variations…
Pharmaceuticals in seven nations
1 May 1985
…pharmaceutical industry, with particular reference to its structure and activities in seven countries – the Federal Republic of Germany, France, Italy, Japan, Switzerland, the United Kingdom and the United States….
Biosimilar Competition: Lessons from Europe and Prospects for the US
1 October 2014
…evolved since 2009 in France, Germany, Italy, Sweden and the UK. The author highlights two key results. Firstly, the market experience varies greatly across product classes and countries – mainly…